DOCSLIB.ORG

TOXICOLOGICAL REVIEW of TETRAHYDROFURAN (CAS No

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TOXICOLOGICAL REVIEW of TETRAHYDROFURAN (CAS No EPA/635/R-11/006F www.epa.gov/iris TOXICOLOGICAL REVIEW OF TETRAHYDROFURAN (CAS No. 109-99-9) In Support of Summary Information on the Integrated Risk Information System (IRIS) February 2012 U.S. Environmental Protection Agency Washington, DC DISCLAIMER This document has been reviewed in accordance with U.S. Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. ii CONTENTS—TOXICOLOGICAL REVIEW OF TETRAHYDROFURAN (CAS No. 109-99-9) LIST OF TABLES ......................................................................................................................... vi LIST OF FIGURES ..................................................................................................................... viii ABBREVIATIONS AND ACRONYMS ...................................................................................... ix FOREWORD ................................................................................................................................. xi AUTHORS, CONTRIBUTORS, AND REVIEWERS ................................................................ xii 1. INTRODUCTION .................................................................................................................. 1-1 2. CHEMICAL AND PHYSICAL INFORMATION ................................................................ 2-1 3. TOXICOKINETICS ............................................................................................................... 3-1 3.1. ABSORPTION .............................................................................................................. 3-1 3.1.1. Gastrointestinal Absorption ................................................................................ 3-1 3.1.2. Respiratory Tract Absorption ............................................................................. 3-4 3.1.3. Dermal Absorption ............................................................................................. 3-5 3.2. DISTRIBUTION ........................................................................................................... 3-5 3.3. METABOLISM ........................................................................................................... 3-10 3.4. ELIMINATION ........................................................................................................... 3-13 3.5. BIOACCUMULATION .............................................................................................. 3-15 3.6. PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS ......................... 3-16 3.7. SUMMARY ................................................................................................................. 3-17 4. HAZARD IDENTIFICATION ............................................................................................... 4-1 4.1. STUDIES IN HUMANS—EPIDEMIOLOGY, CASE REPORTS, CLINICAL CONTROLS .................................................................................................................. 4-1 4.2. SUBCHRONIC AND CHRONIC STUDIES AND CANCER BIOASSAYS IN ANIMALS—ORAL AND INHALATION ................................................................... 4-3 4.2.1. Subchronic Studies ............................................................................................. 4-3 4.2.1.1. Oral ...................................................................................................... 4-3 4.2.1.2. Inhalation ............................................................................................. 4-3 4.2.2. Chronic Studies and Cancer Bioassays ............................................................ 4-10 4.2.2.1. Oral .................................................................................................... 4-10 4.2.2.2. Inhalation ........................................................................................... 4-10 4.3. REPRODUCTIVE/DEVELOPMENTAL TOXICITY STUDIES—ORAL AND INHALATION ............................................................................................................ 4-13 4.3.1. Oral ................................................................................................................... 4-13 4.3.2. Inhalation .......................................................................................................... 4-23 4.4. OTHER DURATION- OR ENDPOINT-SPECIFIC STUDIES ................................. 4-25 4.5. MECHANISTIC DATA AND OTHER STUDIES ..................................................... 4-26 4.6. SYNTHESIS AND EVALUATION OF MAJOR NONCANCER EFFECTS ........... 4-26 4.6.1. Oral ................................................................................................................... 4-26 4.6.2. Inhalation .......................................................................................................... 4-29 iii 4.7. EVALUATION OF CARCINOGENICITY ................................................................ 4-38 4.7.1. Summary of Overall Weight of Evidence ........................................................ 4-38 4.7.2. Synthesis of Human, Animal, and Other Supporting Evidence ....................... 4-39 4.7.3. Mode of Action Information ............................................................................ 4-40 4.7.3.1. Kidney Tumors .................................................................................. 4-40 4.7.3.2. Liver Tumors ..................................................................................... 4-46 4.8. SUSCEPTIBLE POPULATIONS AND LIFE STAGES ............................................ 4-50 4.8.1. Possible Childhood Susceptibility .................................................................... 4-50 4.8.2. Possible Gender Differences ............................................................................ 4-51 4.8.3. Other ................................................................................................................. 4-52 5. DOSE-RESPONSE ASSESSMENTS .................................................................................... 5-1 5.1. ORAL REFERENCE DOSE (RfD) ............................................................................... 5-1 5.1.1. Choice of Principal Study and Candidate Critical Effects—with Rationale and Justification ........................................................................................................ 5-1 5.1.2. Methods of Analysis ........................................................................................... 5-3 5.1.3. RfD Derivation—Including Application of Uncertainty Factors (UFs) ............. 5-5 5.1.4. Previous RfD Assessment .................................................................................. 5-7 5.2. INHALATION REFERENCE CONCENTRATION (RfC) ......................................... 5-7 5.2.1. Choice of Principal Study and Critical Effect—with Rationale and Justification ........................................................................................................ 5-7 5.2.2. Methods of Analysis ......................................................................................... 5-11 5.2.2.1. Calculation of HECs .......................................................................... 5-11 5.2.2.2. Dose-Response Modeling .................................................................. 5-12 5.2.3. RfC Derivation—Including Application of Uncertainty Factors (UFs) ........... 5-14 5.2.4. Previous RfC Assessment ................................................................................. 5-16 5.3. CANCER ASSESSMENT ........................................................................................... 5-16 5.3.1. Evaluation of Inhalation Cancer Data .............................................................. 5-16 5.3.2. Previous Cancer Assessment ............................................................................ 5-18 6. MAJOR CONCLUSIONS IN THE CHARACTERIZATION OF HAZARD AND DOSE RESPONSE............................................................................................................................ 6-1 6.1. HUMAN HAZARD POTENTIAL ................................................................................ 6-1 6.1.1. Oral Noncancer ................................................................................................... 6-1 6.1.2. Inhalation Noncancer .......................................................................................... 6-2 6.1.3. Cancer ................................................................................................................. 6-4 7. REFERENCES ....................................................................................................................... R-1 APPENDIX A. SUMMARY OF EXTERNAL PEER REVIEW AND PUBLIC COMMENTS AND DISPOSITION ............................................................................................................ A-1 APPENDIX B. DOSE-RESPONSE MODELING .....................................................................B-1 B.1. NONCANCER ENDPOINTS ...................................................................................... B-1 B.1.1. Methods ............................................................................................................. B-1 B.1.2. Modeling Results for Noncancer Effects Resulting from Oral Exposure .........B-4 B.1.3. Modeling Results for Noncancer Effects Resulting from Inhalation Exposure ..........................................................................................................B-18
Load more

Recommended publications
  • Energy-Saving Reduced-Pressure Extractive Distillation with Heat
    Energy-Saving Reduced-Pressure Extractive Distillation with Heat Integration for Separating the Biazeotropic Ternary Mixture Tetrahydrofuran–Methanol–Water Jinglian Gu, Xinqiang You, Changyuan Tao, Jun Li, Vincent Gerbaud To cite this version: Jinglian Gu, Xinqiang You, Changyuan Tao, Jun Li, Vincent Gerbaud. Energy-Saving Reduced- Pressure Extractive Distillation with Heat Integration for Separating the Biazeotropic Ternary Mixture Tetrahydrofuran–Methanol–Water. Industrial and engineering chemistry research, American Chemical Society, 2018, 57 (40), pp.13498-13510. 10.1021/acs.iecr.8b03123. hal-01957130 HAL Id: hal-01957130 https://hal.archives-ouvertes.fr/hal-01957130 Submitted on 17 Dec 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. OATAO is an open access repository that collects the work of Toulouse researchers and makes it freely available over the web where possible This is an author’s version published in: http://oatao.univ-toulouse.fr/21066 Official URL: https://doi.org/10.1021/acs.iecr.8b03123 To cite this version: Gu, Jinglian and You, Xinqiang and Tao, Changyuan and Li, Jun and Gerbaud, Vincent Energy-Saving Reduced-Pressure Extractive Distillation with Heat Integration for Separating the Biazeotropic Ternary Mixture Tetrahydrofuran–Methanol–Water.
    [Show full text]
  • Poly(Ethylene Oxide-Co-Tetrahydrofuran) and Poly(Propylene Oxide-Co-Tetrahydrofuran): Synthesis and Thermal Degradation
    Revue Roumaine de Chimie, 2006, 51(7-8), 781–793 Dedicated to the memory of Professor Mircea D. Banciu (1941–2005) POLY(ETHYLENE OXIDE-CO-TETRAHYDROFURAN) AND POLY(PROPYLENE OXIDE-CO-TETRAHYDROFURAN): SYNTHESIS AND THERMAL DEGRADATION Thomas HÖVETBORN, Markus HÖLSCHER, Helmut KEUL∗ and Hartwig HÖCKER Lehrstuhl für Textilchemie und Makromolekulare Chemie der Rheinisch-Westfälischen Technischen Hochschule Aachen, Pauwelsstr. 8, 52056 Aachen, Germany Received January 12, 2006 Copolymers of tetrahydrofuran (THF) and ethylene oxide (EO) (poly(THF-co-EO) and THF and propylene oxide (PO) (poly(THF-co-PO) were obtained by cationic ring opening polymerization of the monomer mixture at 0°C using boron trifluoride etherate (BF3.OEt2) as the initiator. From time conversion plots it was concluded that both monomers are consumed from the very beginning of the reaction and random copolymers are obtained. For poly(THF-co-PO) the molar ratio of repeating units was varied from [THF]/[PO] = 1 to 10; the molar ratio of monomers in the feed corresponds to the molar ratio of repeating units in the copolymer. Thermogravimetric analysis of the copolymers revealed that both poly(THF-co-EO) and poly(THF-co-PO) decompose by ca. 50°C lower than poly(THF) and by ca. 100°C lower than poly(EO); 50% mass loss is obtained at T50 = 375°C for poly(EO), T50 = 330°C for poly(THF) and at T50 = 280°C for both copolymers. The [THF]/[PO] ratio does not influence the decomposition temperature significantly as well. For the copolymers the activation energies of the thermal decomposition (Ea) were determined experimentally from TGA measurements and by density functional calculations on model compounds on the B3LYP/6-31+G* level of theory.
    [Show full text]
  • Protocol Title: Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
    Protocol Title: Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency NCT #: 02019667 Date: 02.13.2020 Explanation of dates: The protocol uploaded to the Documents Section of clinicaltrials.gov represents the final IRB approved version of the protocol. The study team submitted the final amended version of the protocol on March 26, 2019, which was approved by the IRB on April 3, 2019. This version of the protocol was submitted to the IRB for final Continuing Review and was approved by the IRB on August 8, 2019. Protocol Title: Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency Abbreviated Title: SGS-742 in SSADH Deficiency Protocol Number: 14-N-0033 Date of This Submission/Version: March 26, 2019/Version 17 Principal Investigator [email protected] Sara Inati M.D. OCD NINDS 10/7-5680 301-435-6269 Adjunct Principal Investigator Phillip L. Pearl, M.D Boston 300 Longwood 202- 884-5439 [email protected] Children’s Avenue Hospital, 9th floor Boston, MA Boston, MA 02115 Lead Associate Investigator William H Theodore CES/NINDS 10/7D-43 301-496-1505 [email protected] MD Associate Investigators Rosemarie NINDS CTU 10-CRC [email protected] Cuento CRNP 7-5644 301-451-9284 John CNMC NEUROLOGY [email protected] Schreiber MD Washington DC 202-884-5439 Eric BNU DIR NINDS 10/7D-41 [email protected] Wassermann MD K Michael Professor and Chair) PBS Building [email protected] Gibson PhD WSU College of room 347 Pharmacy 412 E. Spokane Falls Blvd Spokane, WA 99202
    [Show full text]
  • Tetrahydrofuran
    SOME CHEMICALS THAT CAUSE TUMOURS OF THE URINARY TRACT IN RODENTS VOLUME 119 This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 6–13 June 2017 LYON, FRANCE - 2019 IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS TETRAHYDROFURAN 1. Exposure Data Boiling point: 65–66 °C (EPA, 2012) Melting point: −108.44 °C (ECHA, 2018) 1.1 Identification of the agent Relative density: 0.883 at 25 °C (water, 1) (ECHA, 2018) 1.1.1 Nomenclature Solubility: Miscible in water (ECHA, 2018) Chem. Abstr. Serv. Reg. No.: 109-99-9 Volatility: Vapour pressure, 19.3 kPa at 20 °C (IPCS, 1997) EC/List No.: 203-726-8 Relative vapour density: 2.5 (air = 1); relative Chem. Abstr. Serv. name: Tetrahydrofuran density of the vapour/air mixture at 20 °C IUPAC systematic name: Oxolane (air = 1): 1.28 (IPCS, 1997) Synonyms: Butane alpha,delta-oxide; butane, Stability: Tetrahydrofuran is prone to oxida- 1,4-epoxy-; cyclotetramethylene oxide; dieth- tion to peroxides, butyric acid, butyralde- ylene oxide; 1,4-epoxybutane; furan, tetra- hyde, and related compounds, mainly on hydro-; furanidine; hydrofuran; oxacyclo- ageing and in the presence of light, heat, pentane; tetramethylene oxide; THF and moisture. The formation of peroxides can be retarded by adding stabilizers such as 1.1.2 Structural and molecular formulae, and hydroquinone or 2,6-di-tert-butyl-p-cresol at relative molecular mass 250 mg/kg (Coetzee & Chang, 1985; Müller, 2012). O Flash point: −14.5 °C
    [Show full text]
  • United States Patent 0 Ice Patented Jan
    3,489,528 United States Patent 0 ice Patented Jan. 13, 1970 1 2 number of (BHZNHZ) groups, but the product is con 3,489,528 PREPARATION OF POLYAMINOBORANES sistent in composition, as shown by infra-red and ele William E. Zanieski, Pittsburgh, Pa., assignor to Mine mental analyses, and the average value of n is about 4. Safety Appliances Company, a corporation of In another example a solution of THF-EH3 contain— Pennsylvania ing 2.99 g. of B2H6 in 150 ml. of THF was prepared N0 Drawing. Filed Apr. 5, 1965, Ser. No. 445,707 in the same manner as the previous example and the Int. Cl. C01b 21/00 solution was warmed to -30° C. 3.12 g. of gaseous US. Cl. 23—358 6 Claims ammonia was bubbled into and dissolved in the solution at —30° C. and the resultant clear solution was warmed to 0° C, at which temperature hydrogen was evolved and polyaminoborane, identical to that obtained in the ABSTRACT OF THE DISCLOSURE previous example, precipitated from the reaction mix Ammonia and diborane are reacted in tetrahydrofuran ture. at a temperature below about —30° C.; polyaminoboranes ‘Although the invention is not limited to any particular are precipitated when the reaction mixture is warmed. 15 reaction mechanism, it appears that the reaction of NH3 Aging of an ammonia solution of the polyaminoboranes and BZHS in THF forms an intermediate that is formed so produced yields an ammonia insoluble, more highly and is stable only at temperatures below about —30° C. polymerized polyaminoborane. and that this intermediate decomposes at temperatures above about —30° C.
    [Show full text]
  • Clinical Trial of the Neuroprotectant Clomethiazole in Coronary Artery Bypass Graft Surgery a Randomized Controlled Trial Robert S
    Anesthesiology 2002; 97:585–91 © 2002 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Clinical Trial of the Neuroprotectant Clomethiazole in Coronary Artery Bypass Graft Surgery A Randomized Controlled Trial Robert S. Kong, F.R.C.A.,* John Butterworth, M.D.,† Wynne Aveling, F.R.C.A.,‡ David A. Stump, M.D.,† Michael J. G. Harrison, F.R.C.P.,§ John Hammon, M.D.,ʈ Jan Stygall, M.Sc.,# Kashemi D. Rorie, Ph.D.,** Stanton P. Newman, D.Phil.†† Background: The neuroprotective property of clomethiazole THE efficacy of coronary artery bypass surgery in the has been demonstrated in several animal models of global and relief of angina and in some circumstances in enhancing Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/97/3/585/335909/0000542-200209000-00011.pdf by guest on 29 September 2021 focal brain ischemia. In this study the authors investigated the life expectation is now accepted. It is a tribute to the low effect of clomethiazole on cerebral outcome in patients under- mortality of the procedure that interest is now focused going coronary artery bypass surgery. Methods: Two hundred forty-five patients scheduled for on the neurologic and neuropsychological complica- 1–3 coronary artery bypass surgery were recruited at two centers tions. Adverse neurologic outcomes have been found and prospectively randomized to clomethiazole edisilate to occur in 2–6% of patients and neuropsychological (0.8%), 225 ml (1.8 mg) loading dose followed by a maintenance deficits in 10–30%.4–6 These complications are consid- dose of 100 ml/h (0.8 mg/h) during surgery, or 0.9% NaCl ered to be ischemic in nature, being a consequence of (placebo) in a double-blind trial.
    [Show full text]
  • Tetrahydrofuran (THF)
    Tetrahydrofuran (THF) Typical Physical Properties of THF Molecular Weight 72.11 g/mol Empirical Formula C4H8O Appearance Colorless Freezing Point ‐108°C (‐ 164.4°F) Flash Point – Closed Cup ‐20°C (‐4°F) Boiling Point @ 760mmHg 66°C (150.8°F) Autoignition Temperature 230°C (446°F) Density @ 20°C 0.89 kg/l Tetrahydrofuran (THF) is a clear, colorless liquid with 7.43 lb/gal an ether‐like odor. The principal end uses of THF Vapor Pressure @ 20°C 193 hPa include PTMEG, pharmaceutical solvent, adhesives, PVC cement and magnetic tape. Due to its' tendency Evaporation Rate (nBuAc = 1) 8 to form peroxides during storage, THF is inhibited with Solubility @ 20°C (in Water) Complete BHT. Refractive Index @ 20°C 1.407 CAS number Viscosity @ 20°C 0.516 cP Lower Flammability in Air 1.5% v/v 109‐99‐9 Upper Flammability in Air 12.4% v/v Synonyms Note: The properties reported above are typical physical properties. Monument Chemical in no way guarantees that the 1,4‐epoxybutane; Cyclotetramethylene oxide; Butane product from any particular lot will conform exactly to the given .alpha.,.delta.‐oxide values. Health and safety information Under current U.S. OSHA's Hazardous Communication program THF is classified as a flammable liquid, can cause eye and respiratory irritation. Keep the material away from heat sources, hot surfaces, open flames, and sparks. Use only in a well‐ventilated area. Observe good industrial hygiene practices and use appropriate Personal Protective Equipment. For full safety information please refer to the Safety Data Sheet. Storage and Handling specific product Technical Data Sheet (TDS) is accurate, but makes no representations as to the sufficiency or THF should be stored only in tightly closed, properly completeness of the product or information in this TDS vented containers away from heat, sparks, open flame and makes no commitment to correct or bring up‐to‐date or strong oxidizing agents.
    [Show full text]
  • A Retrospective Comparison of Inappropriate Prescribing Of
    Schjøtt and Aßmus BMC Medical Informatics and Decision Making (2019) 19:102 https://doi.org/10.1186/s12911-019-0821-0 RESEARCHARTICLE Open Access A retrospective comparison of inappropriate prescribing of psychotropics in three Norwegian nursing homes in 2000 and 2016 with prescribing quality indicators Jan Schjøtt1,2* and Jörg Aßmus3 Abstract Background: Inappropriate prescribing of psychotropics is a persistent and prevalent problem in nursing homes. The present study compared inappropriate prescribing of psychotropics in nursing homes 16 years apart with prescribing quality indicators. The purpose was to identify any change in inappropriate prescribing of relevance for medical informatics. Methods: Three Norwegian nursing homes were audited in 2000 and 2016 with regard to prescribing quality. Psychotropics among 386 patients in 2000, and 416 patients in 2016, included combinations of antidepressants, antipsychotics, anxiolytics-hypnotics, and antiepileptics. Prescribing quality indicators included psychotropic polypharmacy (defined as concurrent use of three or more psychotropics) and potential inappropriate psychotropic substances or combinations. Furthermore, potential clinically relevant psychotropic interactions were classified as pharmacodynamic or pharmacokinetic using an interaction database. The first ranked (most important) interaction in each patient was selected with the following importance of categories in the database; recommended action > documentation > severity. Three levels (from low to high) within each category were used for ranking. Results: From 2000 to 2016, psychotropic polypharmacy increased from 6.2 to 29.6%, potential inappropriate psychotropic substances was reduced from 17.9 to 11.3% and potential inappropriate psychotropic combinations increased from 7.8 to 27.9%. Changes in polypharmacy and combinations were predominantly associated with prescribing of anxiolytics-hypnotics.
    [Show full text]
  • Pharmacological Treatments in Insomnia
    Pharmacological treatments in insomnia Sue Wilson Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College, London Drugs used in insomnia Licensed for insomnia •GABA-A positive allosteric modulators •melatonin (modified release) •promethazine •diphenhydramine •doxepin (USA) Unlicensed prescribed frequently •antihistamines (and OTC) •antidepressants Sometimes prescribed drugs for psychosis Some GABA-A positive allosteric modulators Drugs acting at the GABA-A benzodiazepine receptor zopiclone zolpidem zaleplon benzodiazepines eg temazepam, lorazepam (safe in overdose, as long as no other drug involved) Drugs acting at the barbiturate/alcohol receptor chloral hydrate/chloral betaine clomethiazole (dangerous in overdose) GABA calms the brain Gamma aminobutyic acid (GABA) is the main inhibitory transmitter in the mammalian central nervous system. It plays the principal role in reducing neuronal excitability and its receptors are prolific throughout the brain, in cortex, limbic system, thalamus and cerebellum sedative Increase anticonvulsant GABA anxiolytic function ataxia, memory effects Effects of GABA-A positive allosteric modulators •These drugs enhance the effect of GABA, the main inhibitory neurotransmitter in the brain •They all produce sedation, sleep promotion, ataxia, muscle relaxation, effects on memory, anticonvulsant effects •Therefore for insomnia the duration of action of the drug is important – these effects are unwanted during the day Effects of these GABA-ergic drugs on sleep EEG/PSG • Appearance of
    [Show full text]
  • Contribution of Cyclopentyl Methyl Ether (CPME) to Green Chemistry
    sustainability / green chemistry Industry perspective Shunji Sakamoto Contribution of Cyclopentyl Methyl Ether (CPME) to Green Chemistry Shunji sakamoto Specialty Chemicals Division, ZEON CORPORATION, 1-6-2 Marunouchi, Chiyoda-ku, Tokyo, 1008246, Japan easy peroxide formation and water miscibility, the demand KEyWORDS for CPME has steadily been growing in the pharmaceutical Cyclopentyl methyl ether, CPME, Green Chemistry, industry as well as in the electronic and fragrance solvent, process, ICH. industries. Also, CPME has been registered or listed in the corresponding legislations for new chemical substances of United States of America, Canada, European Union, ABSTRACT Japan, South Korea, China and Chinese Taipei, and is commercially available in these countries and regions as Cyclopentyl methyl ether (CPME) is an alternative well as others including India. solvent and has preferable properties including higher In this article, I answer the question why CPME is “Green” hydrophobicity, lower formation of peroxides and better even though it is derived from petroleum. stability under acidic and basic conditions compared to other traditional ether solvents such as tetrahydrofuran. Due to the above unique properties, CPME has particular UNIQUE FEATURES OF CPME 24 advantages and renders some conventional reaction sequences in one pot or easier process as a result of CPME is an asymmetric aliphatic ether having a cyclopentyl solvent unification and facile isolation of the products, group. It has seven unique features attributed to its structure which contribute to Green Chemistry as well as to (Table 1). process innovation. CPME meets eight definitions out of the 12 Principles of Green Chemistry (1) because of Extremely lower miscibility with water the above characteristics as well as its manufacturing The solubility of CPME in water is only 1.1% and that of water process and its applications.
    [Show full text]
  • Boendedok 2020 Manual För Intervjuformulären
    BoendeDOK 2020 Manual för intervjuformulären Mikael Dahlberg Mats Anderberg Helen Falck Innehållsförteckning Introduktion ___________________________________________________ 4 BoendeDOK __________________________________________________ 6 Inskrivningsintervju __________________________________________ 6 Avstämningsintervju __________________________________________ 7 Utskrivningsintervju __________________________________________ 7 Frågeområden i BoendeDOK ___________________________________ 7 Hantering och förvaring av DOK-material _________________________ 8 Kontaktpersonens roll _________________________________________ 8 Kodning i BoendeDOK ________________________________________ 9 Tidsintervaller ______________________________________________ 10 Frågor om förändring ________________________________________ 10 Att i efterhand ändra intervjusvar _______________________________ 11 Inför intervjun - Klientens samtycke ____________________________ 11 Under intervjun _____________________________________________ 12 Återkoppling av Inskrivningsintervjun ___________________________ 12 BoendeDOK Inskrivningsformulär ________________________________ 16 Intervjuinformation __________________________________________ 16 A. Administrativa uppgifter ___________________________________ 16 B. Bakgrundsinformation _____________________________________ 17 C. Boende _________________________________________________ 17 D. Relationer _______________________________________________ 20 E. Myndighets- och vårdkontakter ______________________________ 21
    [Show full text]
  • Q3C (R8): Impurities: Guideline for Residual Solvents Step 2B
    04 May 2020 EMA/CHMP/ICH/213867/2020 Committee for Medicinal Products for Human Use Q3C (R8): Impurities: guideline for residual solvents Step 2b Transmission to CHMP 30 April 2020 Adoption by CHMP 30 April 2020 Release for public consultation 4 May 2020 Deadline for comments 30 July 2020 Comments should be provided using this template. The completed comments form should be sent to [email protected] Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. PDE for 2-Methyltetrahydrofuran, Cyclopentyl Methyl Ether, and Tertiary-Butyl Alcohol INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE IMPURITIES: GUIDELINE FOR RESIDUAL SOLVENTS Q3C(R8) PDE FOR 2-METHYLTETRAHYDROFURAN, CYCLOPENTYL METHYL ETHER, AND TERTIARY-BUTYL ALCOHOL Draft version Endorsed on 25 March 2020 Currently under public consultation Note : This document contains only the PDE levels for three solvents: 2- methyltetrahydrofuran, cyclopentylmethylether and tert-butanol that were agreed to be included in the ICH Q3C(R8) revision. Further to reaching Step 4, these PDEs would be integrated into a complete Q3C(R8) Guideline document. At Step 2 of the ICH Process, a consensus draft text or guideline, agreed by the appropriate ICH Expert Working Group, is transmitted by the ICH Assembly to the regulatory authorities PDE for 2-Methyltetrahydrofuran, Cyclopentyl Methyl Ether, and Tertiary-Butyl Alcohol of the ICH regions for internal and external consultation, according to national or regional procedures.
    [Show full text]